The Hellenic Competition Authority rules that the decision of a dominant pharmaceutical firm to stop supplying the wholesalers and distribute the pharmaceuticals itself breaches the Competition Act but not Art. 82 EC despite the effect on trade between Member States (GlaxoSmithKline / Syfait)

THE FACTS The dispute between GlaxoSmithKline (hereinafter “GSK”) and the Greek pharmaceutical wholesalers has its routes in 2000, when associations of the latter (amongst them “Sineterismos Farmakopion Etolias & Akarnanias”, “SYFAIT”) submitted numerous complaints to the Hellenic Competition Authority (hereinafter “HCA”) against GSK seeking to declare that the conduct of GSK AEBE (the Greek subsidiary) and its parent company GSK PLC in relation to the distribution of the drugs Lamictal, Imigran and Serevent was incompatible with article 2 of the Greek Competition Act 703/77 (hereinafter “GCA”) and article 82 EC Treaty. GSK had been supplying the complainants with those drugs, which the latter had in turn been supplying to their members (Greek pharmacies), so as to cover only - as they

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Stavros Niarchos Foundation Cultural Center (SNFCC) (Kallithea)

Quotation

Kleopatra Koutra, The Hellenic Competition Authority rules that the decision of a dominant pharmaceutical firm to stop supplying the wholesalers and distribute the pharmaceuticals itself breaches the Competition Act but not Art. 82 EC despite the effect on trade between Member States (GlaxoSmithKline / Syfait), 1 September 2006, e-Competitions Effect on interstate trade, Art. N° 12411

Visites 8205

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues